Paul Tudor Jones Edwards Lifesciences Corp Call Options Transaction History

Tudor Investment Corp Et Al

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$84.3 - $94.31 $244,470 - $273,499	2,900 New	2,900 $267,000
Q4 2023 Feb 14, 2024	BUY	$61.71 - $77.76 $376,431 - $474,336	6,100 New	6,100 $465,000
Q2 2023 Aug 14, 2023	BUY	$81.41 - $94.33 $341,922 - $396,186	4,200 Added 140.0%	7,200 $679,000
Q1 2023 May 15, 2023	SELL	$74.26 - $84.51 $1.16 Million - $1.32 Million	-15,600 Reduced 83.87%	3,000 $248,000
Q4 2022 Feb 14, 2023	BUY	$68.3 - $87.44 $396,140 - $507,152	5,800 Added 45.31%	18,600 $1.39 Million
Q3 2022 Nov 14, 2022	BUY	$82.37 - $107.29 $576,590 - $751,030	7,000 Added 120.69%	12,800 $1.06 Million
Q2 2022 Aug 15, 2022	BUY	$86.5 - $128.27 $112,450 - $166,751	1,300 Added 28.89%	5,800 $554,000
Q1 2022 May 16, 2022	BUY	$101.96 - $128.34 $458,820 - $577,530	4,500 New	4,500 $529,000

1,417

469M

2.44M

2.65M

Ticker EW
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 618,259,968
Market Cap $40.5B
Description
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.